HOME >> BIOLOGY >> NEWS
Premier international meeting provides latest news and issues in blood disorders

(San Diego, Calif., December 5, 2003) More than 20,000 physicians and scientists from around the world will gather for the 45th Annual Meeting of the American Society of Hematology (ASH), the premier multidisciplinary event in blood disease research, which takes place December 6 9, 2003, at the San Diego Convention Center. Researchers and other experts will present the latest breakthrough findings in the field of hematology, covering topics ranging from leukemia and lymphoma to thrombosis and stem cells.

"The ASH annual meeting is the premier event for academic and practicing hematologists throughout the world, providing a unique forum for hematologists to learn about scientific and clinical advances in the area of hematology research," said Ronald Hoffman, M.D., President of the American Society of Hematology.

Hematology is a subspecialty of internal medicine involving the study of blood, which affects all organs and virtually every human function. Hematologists treat patients with a wide range of blood-related conditions, including hemophilia, sickle cell anemia, HIV-AIDS, leukemias and lymphomas, and blood clotting disorders.

The Plenary Policy Forum (scheduled for Sunday, December 7, from 12:15 p.m. to 1:15 p.m. PST), will address health insurance coverage issues in the United States, and will feature the Honorable John Kitzhaber, M.D., former governor of Oregon. The discussion will address the increasing number of uninsured, a national problem affecting practicing physicians and their patients. Immediately following is the Plenary Scientific Session (1:15 p.m. to 3:45 p.m. PST), during which investigators chosen by ASH will present state-of-the-art research in the field of hematology. Presented abstracts will report on advances related to lymphoma, deep vein thrombosis, pediatric acute lymphoblastic leukemia and gene expression profiling, and polycythemia vera.

The Presidential Symposium (schedu
'"/>

Contact: Aimee Frank
afrank@spectrumscience.com
202-955-6222
American Society of Hematology
5-Dec-2003


Page: 1 2 3

Related biology news :

1. Premier international cancer meeting
2. Joslin President awarded medal from international diabetes organization
3. Increasing international insect threat to stored food
4. Ecologist calls for creation of an international panel to assess human behavior
5. Cutting-edge cancer researchers sought for international recognition
6. AACR: The premier international meeting for developments in cancer research
7. Principal investigators named for international scholars in breast cancer research program
8. Rice bioengineer wins international design contest
9. University of Minnesota professors to speak at symposium on international trade
10. AAAS hosts Battle of the Brains to choose area student for international competition
11. HHMI international programs build science capacity in developing countries

Post Your Comments:
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... available in pharmacies and health stores, phosphatidylserine is ... and soy. Proven to improve cognition and slow ... people experiencing memory impairment. Now a team headed ... of Tel Aviv University,s Department of Human ... supplement improves the functioning of genes involved in ...
(Date:5/21/2013)... Try staying fit in space, where living quarters are ... That,s the challenge a group of Michigan State University ... grant from NASA. Their goal is to keep astronauts ... could give astronauts the best exercise regimen there is, ... it, it isn,t going to help," said project leader ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... Miami, FL (PRWEB) May 21, 2013 ... and breakouts as contributor to acne. Recently physicians from ... effects of mental stress on the skin, and suggested ... to help reduce the chemicals produced from stress that ... aside from the negative feelings acne brings about, stress ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome ... use its proprietary methodologies and expertise in genomic ... kinase targets in collaboration with Blueprint Medicines.  PGDx ... at identifying genomic alterations in tumors, and Blueprint ... kinase inhibitors for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
Cached News: